November 14, 2016 09:16 AM ESTUpdated 10:59 AM

Novartis’ ‘breakthrough’ AML drug gets accelerated FDA review; Ocular surges on positive PhIII eye study

Shehla Shakoor

Managing Director

Novartis will get a quick decision from the FDA on its application for PKC412 (midostaurin), its FLT3 drug for acute myeloid leukemia. The agency is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis’ ‘breakthrough’ AML drug gets accelerated FDA review; Ocular surges on positive PhIII eye study

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lexicon ends commercial work to focus on R&D

Are programs with compounded GLP-1s safe for your population?

No­var­tis’ ‘break­through’ AML drug gets ac­cel­er­at­ed FDA re­view; Oc­u­lar surges on pos­i­tive PhI­II eye study

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Lex­i­con ends com­mer­cial work to fo­cus on R&D

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Novartis’ ‘breakthrough’ AML drug gets accelerated FDA review; Ocular surges on positive PhIII eye study

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lexicon ends commercial work to focus on R&D

Are programs with compounded GLP-1s safe for your population?